tarenflurbil

06/01/2009 - "Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD."
06/01/2008 - "Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial."
09/20/2016 - "Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease."
09/01/2010 - "Tarenflurbil in patients with mild Alzheimer's disease."
03/01/2010 - "Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed."

12/16/2009 - "Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. "
06/01/2008 - "Patients with mild AD in the 800 mg tarenflurbil group had lower rates of decline than did those in the placebo group in activities of daily living (ADCS-ADL difference in slope 3.98 [95% CI 0.33 to 7.62] points per year, effect size [reduction from placebo decline rate] 46.4%, Cohen's d 0.45; p=0.033) and global function (CDR-sb difference -0.80 [-1.57 to -0.03] points per year, effect size 35.7%, Cohen's d 0.42; p=0.042); slowing of cognitive decline did not differ significantly (ADAS-cog difference -1.36 [-4.07 to 1.36] points per year, effect size 33.7%, Cohen's d 0.20; p=0.327). "
12/16/2009 - "Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial."
07/01/2013 - "We applied hierarchical Bayesian analysis with cognitive processing (HBCP) models to the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and MCI (mild cognitive impairment) Screen word list memory task data from 14 Alzheimer's disease AD patients of the Myriad Pharmaceuticals' phase III clinical trial of Flurizan (a γ-secretase modulator) versus placebo. "

01/01/2016 - "There was significantly increased risk of infections (OR 1.36, 95% CI 1.13-1.63; p < 0.001) in the subgroup analysis excluding tarenflurbil. "
04/09/2010 - "The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. "
12/16/2009 - "The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. "

03/01/2021 - "The drug candidate TMP-001 is currently under evaluation for the early treatment of Multiple Sclerosis. "
01/01/2019 - "Since many drugs in the therapy scheme of multiple sclerosis (MS) are applied parenterally with significant side effects, oral treatment is the most accepted therapy option for chronic diseases like MS. The drug candidate TMP-001, which has disease-modifying properties, can be applied orally. "

04/09/2010 - "The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. "
12/16/2009 - "The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. "